The Outpatient Prescribing of Silver Sulfadiazine in Al-Kharj

Nehad J. Ahmed

1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.

Author’s contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

ABSTRACT

Aim: The aim of the present study was to describe the outpatient prescription of silver sulfadiazine in Al-Kharj.

Methodology: This study was conducted in a public hospital in Alkharj. The data were collected from the outpatient pharmacy in the hospital and includes outpatients who received silver sulfadiazine in 2018.

Results: All of the silver sulfadiazine prescriptions were prescribed for 7 days. The prescriptions were made mainly by residents (96.67%). Most of the prescriptions were prescribed by emergency department (90.00%).

Conclusion: The use of silver sulfadiazine was uncommon in Alkharj possibly due to the use of effective natural medicines. Silver sulfadiazine could lead to several adverse effects so it is important to increase the awareness about the wise use of silver sulfadiazine and other topical antibiotics.

Keywords: Antibiotic; outpatient; prescribing; silver sulfadiazine.

1. INTRODUCTION

The process of medication prescribing is not an easy process and includes numerous aspects such as deciding that a drug is indicated, choosing the right medicine, monitoring for effectiveness and toxicity, determining the suitable dosage regimen in line with the
patient's physiologic status, determining when the patient need health care workers’ consultation, and educating patient about the predicted adverse effects [1].

Consuming medications unsuitably leads to many avoidable adverse events [1]. The misuse, underuse, or overuse of medicines may cause widespread health hazards like adverse events and antibiotic resistance; these hazards cause an increased mortality and morbidity as well as wastage of the limited resources [2].

Silver sulfadiazine belongs to sulfa antibiotics class and is used with other treatments to treat and prevent wound infections in patients with serious burns. It works by stopping bacteria growth and helps in lessening the spreading of the bacteria to the blood or to the surrounding skin [3]. Silver sulfadiazine is prescribed only with a doctor’s prescription and is available as a cream dosage forms [4]. The most common side effects of this drug were pain, itching of treated skin, burning, discoloration of skin and mucous membranes, and upset stomach [5]. Frederick and Fuller reported that silver sulfadiazine cream has an enviable safety record in burn treatment and that the presence of side effects is no longer an indication to discontinue silver sulfadiazine burn wound therapy [6].

It is essential to study the prescribing patterns of different medicines because it determines the exposure of the patients to these medicines and also, has a crucial role in the management of the different diseases [7]. The study of medication prescribing pattern is a part of pharmaco-epidemiology and describes the amount, types, and determinants of medication use [8]. A previous study reported that the foremost aim of medication utilization studies is to facilitate the correct and rational medications use for different patients [9]. So, the aim of the present study was to describe the outpatient prescribing of silver sulfadiazine in Al-Kharj.

2. METHODOLOGY

The Study was conducted in a public hospital in Alkharj. The data of patients who received silver sulfadiazine during 2018 were collected from outpatient pharmacy and excluded patients from inpatient or emergency pharmacy. Moreover, the prescriptions that didn’t contain silver sulfadiazine were also excluded.

The collected data included several parts. The first part contained the gender, age and nationality of the patients, second part contained the number of patients receiving silver sulfadiazine during the different months in 2018, the third part contained data about the level of the prescribers, and the last part contained data about the departments that prescribed silver sulfadiazine.

The research was approved by the IRB committee with IRB Log No: 20-131E. The data were collected and analyzed using Excel software and represented as percentages and frequencies.

3. RESULTS AND DISCUSSION

In 2018, the outpatient pharmacy in the hospital prescribed silver sulfadiazine to 30 patients. Most of the patients were males (70.00%). The age of 26.67% of the patients was between 30 and 39 years and the age of 23.33% of them was less than 10 years old. The personal data of the patients are shown in Table 1.

More than 73 % of the prescriptions were in the first half of 2018 (Table 2).

| Variable          | Category         | Number | Percentage |
|-------------------|------------------|--------|------------|
| Gender            | Female           | 9      | 30.0       |
|                   | Male             | 21     | 70.00      |
| Age               | Less than 10     | 7      | 23.33      |
|                   | 10-19            | 6      | 20.00      |
|                   | 20-29            | 6      | 20.00      |
|                   | 30-39            | 8      | 26.67      |
|                   | 40-49            | 2      | 6.67       |
|                   | 50-59            | 1      | 3.33       |
| Nationality       | Saudi            | 24     | 80.00      |
|                   | Non- Saudi       | 6      | 20.00      |
Table 2. The number of patients receiving silver sulfadiazine in 2018

| Month     | Number | Percentage |
|-----------|--------|------------|
| January   | 2      | 6.67       |
| February  | 3      | 10.00      |
| March     | 3      | 10.00      |
| April     | 3      | 10.00      |
| May       | 5      | 16.67      |
| June      | 6      | 20.00      |
| July      | 3      | 10.00      |
| August    | 0      | 0.00       |
| September | 2      | 6.66       |
| October   | 2      | 6.66       |
| November  | 1      | 3.33       |
| December  | 0      | 0.00       |

Table 3. The level of the prescribers

| Prescribers Level | Number | Percentage |
|-------------------|--------|------------|
| Specialist        | 1      | 3.33       |
| Resident          | 29     | 96.67      |
| Consultant        | 0      | 0.00       |

Table 4. Prescribing departments

| Department       | Number | Percentage |
|------------------|--------|------------|
| Plastic Surgery  | 3      | 10.00      |
| Emergency        | 27     | 90.00      |
| Total            | 30     | 100.00     |

All of the silver sulfadiazine prescriptions were for 7 days and made mainly by residents (96.67%) (Table 3).

Most of the prescriptions were made by emergency department (90.00%) (Table 4).

The reduction in the use of silver sulfadiazine could be due to the development of resistance to it by several bacterial and also due to the need to use natural agents that could be safer. Herndon reported that there have been reports of the increased resistance of pseudomonas aeruginosa to silver sulfadiazine [10]. They also stated that some strains of the Klebsiella species have been less effectively controlled by it [10]. Additionally, the researcher studied several natural agents to be used instead of silver sulfadiazine. Jewo et al., informed that several natural agents such as moist exposed burn ointment (MEBO) and honey are believed to prevent developing wounds’ infections [13]. Natural agents also could promote healing without causing any of the adverse events that are caused by the chemicals [13]. Moreover, Jewo et al. [13] stated that MEBO is an efficacious and a suitable alternative to conventional silver-based topical treatments for treating partial-thickness burn wounds and that concerns about the toxicity of purified chemicals will continue to make people turn to complementary and alternative medicines (CAM) such as MEBO. According to Yeh et al. [14] low
toxicity, easier handling, cheaper costs, and availability are factors that may promote the use of MEBO and other CAM.

4. CONCLUSION

The use of silver sulfadiazine was uncommon in Alkharj. Its use is decreased due to the use of effective natural medicines such as MEBO. Although the use of silver sulfadiazine is decreased but still could lead to several adverse effects and its inappropriate use could increase the resistance of bacteria to it. It is important to increase the awareness about the wise use of silver sulfadiazine and other topical antibiotics.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the author and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the author.

CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

ETHICAL APPROVALS

The research was approved by the IRB committee with IRB Log No: 20-131E

ACKNOWLEDGEMENT

This Publication was supported by the Deanship of Scientific Research at Prince Sattam bin Abdulaziz University.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Uptodate. Drug prescribing for older adults. Accessed 08Oct 2021. Available:https://www.uptodate.com/contents/drug-prescribing-for-older-adults.
2. Babalola C, Awoleye S, Akinyemi J, Kotila O. Evaluation of prescription pattern in Osun state (southwest) Nigeria. J Publ Health Epidemiol. 2011;3(3):94-98.
3. Webmed. Silver sulfadiazine topical. Accessed 08Oct 2021. Available:https://www.webmd.com/drugs/2/drug-13530/silver-sulfadiazine-topical/details.
4. Mayoclinic. Silver sulfadiazine topical route. Accessed 08Oct 2021. Available:https://www.mayoclinic.org/drugs-supplements/silver-sulfadiazine-topical-route/proper-use/drg-20068819?p=1.
5. Rxlist. Silvadene drug. Accessed 08 Oct 2021. Available: https://www.rxlist.com/silvadene-drug.htm.
6. Frederick W. Fuller, MD, The Side Effects of Silver SulfaDiazine. J. Burn. Care. Res. 2009;30(3):464–470.
7. Summoro TS, Gidebo KD, Kanche ZZ, Woticha EW. Evaluation of trends of drug-prescribing patterns based on WHO prescribing indicators at outpatient departments of four hospitals in southern Ethiopia. Drug Des DevelTher. 2015;9:4551-7.
8. Sjoqvist F, Birkett D. Drug Utilization. In: Bramley DW editor. Introduction to drug utilization research. (WHO booklet) New York: WHO office of publications ;2003.
9. Vanitha M, Vineela M, Benjamin RKP. Prescribing pattern of antibiotics in patients attending ENT OPD in a tertiary care hospital. IOSR-JDMS. 2017;16(9):30-3.
10. Herndon DN. Total burn care. Elsevier Health Sciences; 2007.
11. IsakV, Beerli T, Cozzoio A, Flatz L. A rare case of localized argyria on the face. Case Rep. Dermatol. 2019;11(1), 23-27.
12. Oaks RJ, Cindass R. Silver SulfaDiazine. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available:https://www.ncbi.nlm.nih.gov/books/NBK556054
13. Jewo PI, Fadeyibi IO, Babalola OS, Saalu LC, Benebo AS, Izegbu MC, Ashiru OA. A Comparative Study of the Wound Healing Properties of Moist Exposed Burn Ointment (MEBO) and Silver Sulphadiazine. Ann. Burns Fire Disasters. 2009;22(2):79–82.
14. Yeh GY, Eisenberg DM, Kaptchuk TJ. Systematic review of herbs and dietary supplements used in glycemic control in diabetes. Diabetes Care. 2003;26:1277–1294.

© 2021 Ahmed; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle4.com/review-history/75895